Agios Pharmaceuticals, Inc.AGIO

$34.16+1.08 (+3.26%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$2B

Mid-cap

-8%

2016 — today

10-Year Price

-41%

2016 — today

52-Week Range

$22.34$45.49

Current $34.16· 51%

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Valuation in context

P/E ratio

-4.7

N/A

Not meaningful — company is unprofitable

P/B ratio

1.8

Below average

Below the 10-year average

FCF Yield

-19.2%

Below average

Below the 10-year average

Free · No credit card needed

Get alerted when AGIO is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.